查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球辅助生殖技术市场 - 2023-2030 年
市场调查报告书
商品编码
1316263

全球辅助生殖技术市场 - 2023-2030 年

Global Assisted Reproductive Technology Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概述

2022 年，全球辅助生殖技术市场规模达到 338 亿美元，预计到 2030 年将实现利润丰厚的增长，达到 537 亿美元。在预测期内（2023-2030 年），全球辅助生殖技术市场的复合年增长率预计将达到 6.1%。

辅助生殖技术（ART）推动了生殖医学的发展，提高了生育治疗的成功率、安全性和效率。持续的研究和技术发展有助于更好地了解和管理不孕不育症。因此，该领域不断发展，为寻求生殖援助的个人和夫妇提供了创新的解决方案和治疗方案。

市场动态

主要企业的关键战略有助于推动市场增长

主要企业的关键战略有助于推动市场增长。例如，2021 年 1 月 5 日，著名的妇女保健解决方案提供商 CooperSurgical 收购了为诊所和患者提供冷冻储存软件的知名供应商 Embryo Options。通过此次收购，CooperSurgical 的全套突破性生殖疗法得到了扩展。

与 Embryo Options 合作的诊所将受益于低温保存的胚胎、卵子和精子的自动计费和简化管理，从而增加采集量、降低标本遗弃率和低温库存管理成本。

单亲家庭数量增加将推动市场增长

在整个预测期内，单亲家庭数量的不断增加，以及人们对同性婚礼和辅助生殖技术认识的提高，都可能对 ART 市场的增长产生重要影响。

例如，根据人权运动（HRC）基金会 2022 年的报告，2022 年，同性婚姻合法的国家数量已攀升至 32 个，一些国家的议会或法院程序已经启动，预计这一数字还将进一步上升。由于同性婚姻的增加，对 ART 治疗的需求预计将急剧上升，从而促进该行业的增长。

辅助生殖技术系统的高成本将阻碍市场增长

ART 程序涉及实验室工作，包括精子和卵子检索、受精、胚胎培养和冷冻保存。这些实验室服务所需的专业设备、耗材和专业知识都会增加成本。此外，长期储存冷冻胚胎或配子也会产生持续的维护和储存设施费用。

ART 技术和科技的进步需要不断的研发。在生殖医学领域进行研究、临床试验和创新的成本反映在 ART 系统的总支出中。

COVID-19 影响分析

大流行期间，由于封锁、社会隔离措施和医疗系统不堪重负，许多抗逆转录病毒疗法诊所不得不暂时中止或限制服务。这种干扰导致个人和夫妇的生育治疗推迟或取消，造成了巨大的情感和后勤挑战。

大流行使个人难以进行生育评估和诊断检测。非必要的医疗预约和程序往往被推迟或取消，导致确定和解决生育问题的延误。诊断和治疗的延误进一步延长了许多个人和夫妇的生育之路。

俄乌战争影响分析

据估计，俄乌冲突对全球辅助生殖技术市场的影响不大，原因是该地区的主要市场参与者较少。不过，在预测期内，原材料进出口的影响预计对全球辅助生殖技术市场的增长影响不大。

人工智能的影响分析

人工智能可与胚胎植入前基因检测（PGT）结合使用，分析胚胎的基因和染色体数据。人工智能算法可以识别特定遗传标记与胚胎存活率之间的模式和相关性，帮助预测成功植入的可能性，降低后代患遗传疾病的风险。值得注意的是，虽然人工智能在改善 ART 系统方面具有巨大潜力，但在使用时应始终结合医疗保健专业人员的专业知识和指导。

目 录

第 1 章：研究方法与范围

  • 研究方法
  • 报告的研究目标和范围

第2章：定义和概述

第3章：执行摘要

  • 按技术类型分類的摘要
  • 按流程划分
  • 按最终用户划分
  • 按地区划分

第四章：动态

  • 影响因素
    • 驱动因素
      • 不孕不育率持续上升
      • ART 成功率不断提高
    • 限制因素
      • 辅助生殖技术系统成本高昂
    • 机会
      • ART 使个人和夫妇能够更好地控制自己的生育选择
    • 影响分析

第 5 章：行业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章：COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情况
    • COVID-19 期间的情景
    • COVID-19 后的情况
  • COVID-19 期间的定价动态
  • 供求关系
  • 大流行期间与市场相关的政府倡议
  • 制造商的战略倡议
  • 结论

第7章：按技术类型划分

  • 体外受精（IVF）
  • 人工授精（AI-IUI）
  • 冷冻胚胎置换（FER）
  • 其他

第 8 章：按程序分类

  • 新鲜供体
  • 新鲜非供体
  • 冷冻供体
  • 冷冻非供体
  • 胚胎库

第9章：按最终用户分类

  • 医院
  • 生育诊所
  • 其他

第10章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
      • 亚太其他地区
  • 中东和非洲
    • 特定地区的主要动态

第 11 章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併与收购分析

第十二章 ：公司简介

  • Irvine Scientific (FUJIFILM Corporation)
    • 公司概况
    • 产品组合和说明
    • 财务概况
    • 主要发展
  • CooperSurgical Inc
  • Thermo Fisher Scientific, Inc.
  • Genea Biomedx
  • Microm UK Ltd
  • Hamilton Thorne Inc
  • Merck KGaA
  • Laboratoire CCD
  • Vitrolife AB
  • OvaScience Inc.

第 13 章 ：附录

简介目录
Product Code: MD1496

Market Overview

The global assisted reproductive technology market reached US$ 33.8 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 53.7 billion by 2030. The global assisted reproductive technology market is expected to exhibit a CAGR of 6.1% during the forecast period (2023-2030).

Assisted Reproductive Technology (ART) drives advancements in reproductive medicine, leading to improved success rates, safety, and efficiency of fertility treatments. Ongoing research and technological developments contribute to better understanding and management of infertility. As a result, the field continues to evolve, offering innovative solutions and treatment options to individuals and couples seeking reproductive assistance.

Market Dynamics

The Key Strategies by the Key Players Helps to Drive Market Growth

The key strategies by the key players helps to drive market growth. For instance, on January 5, 2021, CooperSurgical, a prominent provider of women's health care solutions, has acquired Embryo Options, a well-known provider of cryo-storage software for clinics and patients. CooperSurgical's full array of breakthrough reproductive treatments has been expanded with this acquisition.

Clinics that work with Embryo Options benefit from automated billing and streamlined management of cryo-preserved embryos, eggs, and sperm, which leads to increased collections, lower specimen abandonment, and lower cryo-inventory management costs.

The Rising Number of Single Parenting will Drive the Market Growth

The growing number of single parents, as well as increased awareness of same-sex weddings and assisted reproductive technologies, are likely to play a key influence in the growth of the ART market throughout the forecast period.

For instance, according to the Human Rights Campaign (HRC) Foundation's 2022 report, the number of nations where same-sex marriage is legal has climbed to 32 in 2022, with parliamentary or court processes beginning in several countries, and this graph is anticipated to rise further. As a result of the increase in same-sex marriages, demand for ART treatments is predicted to rise dramatically, boosting growth in the maket.

High Cost of Assisted Reproductive Technology Systems will Hamper the Market Growth

ART procedures involve laboratory work, including sperm and egg retrieval, fertilization, embryo culture, and cryopreservation. The specialized equipment, consumables, and expertise required for these laboratory services contribute to the cost. Additionally, long-term storage of frozen embryos or gametes incurs ongoing fees for maintenance and storage facilities.

Advancements in ART techniques and technologies require ongoing research and development. The cost of conducting research studies, clinical trials, and innovation in the field of reproductive medicine is reflected in the overall expense of ART systems.

COVID-19 Impact Analysis

Many ART clinics had to temporarily suspend or limit their services during the pandemic due to lockdowns, social distancing measures, and overwhelmed healthcare systems. This disruption led to the postponement or cancellation of fertility treatments for individuals and couples, causing significant emotional and logistical challenges.

The pandemic made it difficult for individuals to undergo fertility evaluations and diagnostic tests. Non-essential medical appointments and procedures were often postponed or canceled, leading to delays in identifying and addressing fertility issues. This delay in diagnosis and treatment further prolonged the journey to parenthood for many individuals and couples.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global assisted reproductive technology market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global assisted reproductive technology market growth over the forecast period.

Artificial Intelligence Impact Analysis

AI can be used in conjunction with preimplantation genetic testing (PGT) to analyze genetic and chromosomal data from embryos. AI algorithms can identify patterns and correlations between specific genetic markers and embryo viability, helping predict the likelihood of successful implantation and reducing the risk of genetic disorders in offspring. It is important to note that while AI holds great potential in improving ART systems, it should always be used in conjunction with the expertise and guidance of healthcare professionals.

Segment Analysis

The global assisted reproductive technology market is segmented based on technology type, procedure, end user and region.

The In-Vitro Fertilization Accounted for Approximately 53.2% of the Assisted Reproductive Technology Market Share

The ultimate benefit of IVF is a successful pregnancy and a healthy baby. IVF can make this a reality for people who might otherwise be unable to conceive a child. IVF gives women with blocked or damaged fallopian tubes the best chance of producing a child using their own eggs. Furthermore, new product releases and approvals by companies contribute to the segment's growth.

For instance, October. 25, 2022, TMRW Life Sciences, Inc. (TMRW), the company that invented of the world's first automated specimen management platform for frozen eggs and embryos used in in vitro fertilisation (IVF), has announced the opening of the world's most advanced fertility specimen cryostorage facility.

This technologically advanced facility in New York provides a new standard of care directly to patients and fertility clinic partners for the first time, delivering unparalleled levels of transparency into the safety of frozen eggs and embryos at the heart of practically every IVF experience. As a result, the aforementioned elements contribute to segment growth.

Geographical Analysis

North America Accounted for Approximately 43.4% of the Market Share

North America is expected to hold a significant market share in the global assisted reproductive technology market over the forecast period, owing to factors such as rising infertility in the region and public-sector initiatives that are expected to boost market growth over the forecast period.

For instance, infertility is on the rise. Infertile couples are using assisted reproductive technology (ART) at a rate of 5% to 10% each year. According to the United Nations, there were five children for every woman in the globe in 1950. In 2020, there will be two children for every woman on the planet.

In the United States, there has been a long-term reduction in birth and fertility rates, which has been linked to a variety of causes such as women's increased education and professional options, later marriage, improved access to contraception, delayed childbirth, and smaller family size. As a result, infertility rates are rising, which aids regional growth.

Competitive Landscape

The major global players in the assisted reproductive technology market are: Irvine Scientific (FUJIFILM Corporation), CooperSurgical Inc, Thermo Fisher Scientific, Inc., Genea Biomedx, Microm UK Ltd, Hamilton Thorne Inc, Merck KGaA, Laboratoire CCD, Vitrolife AB, OvaScience Inc among others.

Why Purchase the Report?

  • To visualize the global assisted reproductive technology market segmentation based on technology type, procedure, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of assisted reproductive technology market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global assisted reproductive technology market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Technology Type
  • 3.2. Snippet by Procedure
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The constant rise in the infertility rate
      • 4.1.1.2. Improving ART success rates
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of assisted reproductive technology systems
    • 4.1.3. Opportunity
      • 4.1.3.1. ART allows individuals and couples to have greater control over their reproductive choices
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Technology Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 7.1.2. Market Attractiveness Index, By Technology Type
  • 7.2. In Vitro-fertilization (IVF) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Artificial Insemination (AI-IUI)
  • 7.4. Frozen Embryo Replacement (FER)
  • 7.5. Others

8. By Procedure

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 8.1.2. Market Attractiveness Index, By Procedure
  • 8.2. Fresh donor *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Fresh non-donor
  • 8.4. Frozen donor
  • 8.5. Frozen non-donor
  • 8.6. Embryo banking

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospital *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Fertility Clinics
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Plan Type
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Irvine Scientific (FUJIFILM Corporation) *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. CooperSurgical Inc
  • 12.3. Thermo Fisher Scientific, Inc.
  • 12.4. Genea Biomedx
  • 12.5. Microm UK Ltd
  • 12.6. Hamilton Thorne Inc
  • 12.7. Merck KGaA
  • 12.8. Laboratoire CCD
  • 12.9. Vitrolife AB
  • 12.10. OvaScience Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us